Cargando…

FGF21 as a Hepatokine, Adipokine, and Myokine in Metabolism and Diseases

Fibroblast growth factor (FGF) family members are mostly secreted as signaling proteins with diverse functions in development and metabolism. FGF21 is a unique FGF with metabolic, but not proliferative activities. FGF21 is mostly induced by different kinds of stress and acts though FGF receptor 1c w...

Descripción completa

Detalles Bibliográficos
Autor principal: Itoh, Nobuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4083219/
https://www.ncbi.nlm.nih.gov/pubmed/25071723
http://dx.doi.org/10.3389/fendo.2014.00107
_version_ 1782324344484003840
author Itoh, Nobuyuki
author_facet Itoh, Nobuyuki
author_sort Itoh, Nobuyuki
collection PubMed
description Fibroblast growth factor (FGF) family members are mostly secreted as signaling proteins with diverse functions in development and metabolism. FGF21 is a unique FGF with metabolic, but not proliferative activities. FGF21 is mostly induced by different kinds of stress and acts though FGF receptor 1c with β-Klotho as a cofactor in an endocrine or, in parts, autocrine/paracrine manner. Hepatic FGF21 directly acts on white adipocytes to inhibit lipolysis and acts through the brain to increase systemic glucocorticoid levels and suppress physical activity in response to starvation. It also protects against dioxin toxicity. Adipocytic FGF21 induces the browning of white adipose tissue (WAT) and activates brown adipocytes in response to cold exposure. It also acts as an upstream effector of adiponectin in white adipocytes. Myocytic FGF21 protects against diet-induced obesity and insulin resistance, induces the browning of WAT, and protects against cardiac hypertrophy. In addition, Fgf21 polymorphisms are possibly related with metabolic diseases and FGF21 are biomarker of metabolic diseases. These findings indicate that FGF21 plays roles as a hepatokine, adipokine, and myokine in metabolism, injury protection, and diseases.
format Online
Article
Text
id pubmed-4083219
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-40832192014-07-28 FGF21 as a Hepatokine, Adipokine, and Myokine in Metabolism and Diseases Itoh, Nobuyuki Front Endocrinol (Lausanne) Endocrinology Fibroblast growth factor (FGF) family members are mostly secreted as signaling proteins with diverse functions in development and metabolism. FGF21 is a unique FGF with metabolic, but not proliferative activities. FGF21 is mostly induced by different kinds of stress and acts though FGF receptor 1c with β-Klotho as a cofactor in an endocrine or, in parts, autocrine/paracrine manner. Hepatic FGF21 directly acts on white adipocytes to inhibit lipolysis and acts through the brain to increase systemic glucocorticoid levels and suppress physical activity in response to starvation. It also protects against dioxin toxicity. Adipocytic FGF21 induces the browning of white adipose tissue (WAT) and activates brown adipocytes in response to cold exposure. It also acts as an upstream effector of adiponectin in white adipocytes. Myocytic FGF21 protects against diet-induced obesity and insulin resistance, induces the browning of WAT, and protects against cardiac hypertrophy. In addition, Fgf21 polymorphisms are possibly related with metabolic diseases and FGF21 are biomarker of metabolic diseases. These findings indicate that FGF21 plays roles as a hepatokine, adipokine, and myokine in metabolism, injury protection, and diseases. Frontiers Media S.A. 2014-07-07 /pmc/articles/PMC4083219/ /pubmed/25071723 http://dx.doi.org/10.3389/fendo.2014.00107 Text en Copyright © 2014 Itoh. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Itoh, Nobuyuki
FGF21 as a Hepatokine, Adipokine, and Myokine in Metabolism and Diseases
title FGF21 as a Hepatokine, Adipokine, and Myokine in Metabolism and Diseases
title_full FGF21 as a Hepatokine, Adipokine, and Myokine in Metabolism and Diseases
title_fullStr FGF21 as a Hepatokine, Adipokine, and Myokine in Metabolism and Diseases
title_full_unstemmed FGF21 as a Hepatokine, Adipokine, and Myokine in Metabolism and Diseases
title_short FGF21 as a Hepatokine, Adipokine, and Myokine in Metabolism and Diseases
title_sort fgf21 as a hepatokine, adipokine, and myokine in metabolism and diseases
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4083219/
https://www.ncbi.nlm.nih.gov/pubmed/25071723
http://dx.doi.org/10.3389/fendo.2014.00107
work_keys_str_mv AT itohnobuyuki fgf21asahepatokineadipokineandmyokineinmetabolismanddiseases